11282-Lymphomas-Non-Hodgkins-466

Lymphomas

(SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

  • Details

ClinicalTrials.gov ID: NCT01716806
Diagnosis Type: Non-Hodgkins
USOR Number:

  • Address

265 North Broadway
Portland, OR 97227
P: (503) 280-1223

Search by practice name, trial titles, indicators and specific disease types.